Sanofi

NASDAQ:SNY

Drug Manufacturers - General

Healthcare
$47.12 -0.73%

-$0.31 today

Market cap
$113.15B
Beta
0.28
P/E (TTM)
8.5
EPS (TTM)
$8.60
Dividend yield
5.62%
52W Low $41.86High $52.68

Volume 2.32M

Average 2.78M

SNY Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

SanofiNASDAQ: SNY

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of €2.23B rose 17.0% year over year, ahead of the +5.4% change in trailing-twelve-month research & development. Sequentially, it rose 27.8% from the prior quarter. Over 3 fiscal years it compounded at +6.5% a year.

Context

  • Research & development amounted to 16.8% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +17.0% holds above the trailing-twelve-month pace of +5.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
€2.23B+27.8% QoQ
Last fiscal yearDec 2025
€7.84B+6.1% YoY
LTMJun 2026
€8.11B+5.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.0%——
1 year+6.1%——
3-year CAGR+6.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

EUR · from the income statement

Latest · FY2025
7.84B EUR
Year-over-year change
+6.1%
4-year CAGR
+8.3%

Research & Development vs competitors

How SNY compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +5.4% is the 8th highest of 11, against a peer median of +14.2%.
  • Research & development amounts to 16.6% of revenue for SNY, versus a peer median of 20.2%.
SNY Competitors
Research & Development for SNY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 58.11B DKK+28.3%+29.3%17.6%
MRKMerck & Co., Inc.LTM Jun 2026$28.35B USD+65.7%-2.6%42.7%
AZNAstraZeneca PLCLTM Sep 2026$15.01B USD-0.3%+13.4%24.1%
LLYEli Lilly and CompanyLTM Jun 2026$14.6B USD+23.4%+22.9%18.3%
NVSNovartis AGLTM Jun 2026$11.28B USD+9.2%+5.4%20.3%
PFEPfizer Inc.LTM Jun 2026$11.05B USD+7.0%-3.0%17.3%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$10.72B USD+3.1%+1.5%21.8%
GSKGSK plcLTM Jun 2026£9.2B GBP+31.8%+11.1%27.7%
SNYSanofiLTM Jun 2026€8.11B EUR+5.4%+6.5%16.6%
AMGNAmgen Inc.LTM Jun 2026$7.64B USD+19.3%+16.3%20.0%
GILDGilead Sciences, Inc.LTM Jun 2026$6.07B USD+2.7%+5.2%19.9%
Peer median (excluding SNY) —+14.2%+8.3%20.2%

Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue39.18B40.56B41.62B44.29B46.72B
Cost of Revenue12.26B11.88B12.63B13.21B13.05B
Gross Profit26.92B28.68B28.99B31.08B33.67B
Gross Margin68.7%70.7%69.7%70.2%72.1%
Research & Development5.69B6.5B6.51B7.39B7.84B
Selling, General & Admin9.56B8.74B8.93B9.18B10.24B
Operating Expenses18.79B18.52B22.03B23.83B24.07B
Depreciation & Amortization3.35B3.11B4.43B3.59B5.68B
EBITDA11.54B13.51B11.39B11.03B12.48B
EBITDA Margin29.5%33.3%27.4%24.9%26.7%
Operating Income8.13B10.16B6.96B7.25B9.6B
Operating Margin20.7%25.1%16.7%16.4%20.5%
Interest Income3.13M168.96M530.5M457.53M331M
Interest Expense377.37M384.8M512.82M622.58M626M
Other Income / Expenses(289M)(170M)(845M)(494M)(3.58B)
Income Before Tax7.84B9.99B6.12B6.76B6.02B
Pre-Tax Margin20.0%24.6%14.7%15.3%12.9%
Income Tax Expense1.56B1.91B1.02B1.2B1.04B
Net Income6.22B8.37B5.4B5.56B7.81B
Net Margin15.9%20.6%13.0%12.6%16.7%
EPS (Basic)2.493.192.152.193.20
EPS (Diluted)2.493.182.152.193.20
Weighted Avg Shares2.51B2.5B2.5B2.5B2.44B
Weighted Avg Shares (Diluted)2.51B2.5B2.51B2.5B2.44B

Sanofi

NASDAQ:SNY

Intrinsic Alpha fair value

Locked

Current Price

$47.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.